Results 1 to 10 of about 111,189 (247)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

Frontiers in Immunology, 2020
Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively.
Vesna Brglez, Patrick Nachman, Vincent L M Esnault   +2 more
exaly   +3 more sources

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation [PDF]

Majalah Kedokteran Bandung, 2019
Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131I-Rituximab, has been sucessfully used for treatment of B-Cell NHL.
Martalena Ramli, Basuki Hidayat, Sutari Sutari, Sri Setyowati, Veronica Yulianti Susilo   +4 more
doaj   +2 more sources

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma [PDF]

HemaSphere
We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires ...
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming‐Chung Wang, Wojciech Legiec, Stephen Opat, Junvie Pailden, Hillary M. Peltier, Emerenziana Marturano, James P. Dean, Ian W. Flinn   +17 more
doaj   +2 more sources

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases [PDF]

Pharmacology Research & Perspectives
Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on ...
María Larrosa‐García, Irene Agraz Pamplona, Susana Rojo Tolosa, Alberto Jiménez Morales, María Teresa Sanz Martínez, Mónica Martínez Gallo, Roger Colobran, Helena Genestal Vicente, Nerea Moreno Pena, Roxana Paola Bury Macías, José Bruno Montoro Ronsano   +10 more
doaj   +2 more sources

Case series of low dose rituximab for membranous nephropathy; a single centre experience [PDF]

Journal of Nephropathology, 2023
Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries.
Gerry George Mathew, Jayaprakash Varadharajan, Sreedhar Sailapathy   +2 more
doaj   +1 more source

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Frontiers in Immunology, 2023
BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period.
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, Pichaya O-Charoen, Prapaporn Pisitkun, Thanitta Suangtamai, Chavachol Setthaudom, Sonphet Chirasuthat, Kumutnart Chanprapaph   +9 more
doaj   +1 more source

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Frontiers in Immunology, 2021
Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving
Maxime Teisseyre, Maxime Teisseyre, Marion Cremoni, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Thomas Crepin, Sylvia Benzaken, Kévin Zorzi, Vincent Esnault, Vesna Brglez, Vesna Brglez, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +15 more
doaj   +1 more source

RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA

Hematology, Transfusion and Cell Therapy, 2022
Objective: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological.
Taha Ulutan Kars, Zahit Furkan Yorgancı, Osman Yaşkıran, Atakan Tekinalp   +3 more
doaj   +1 more source

Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts [PDF]

Journal of Nephropathology, 2018
Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies.
Mohammad-Reza Tamadon, Jamileh Moghimi, Hamed Rezaei   +2 more
doaj   +1 more source

Rituximab resistance [PDF]

Best Practice & Research Clinical Haematology, 2011
Rituximab has become a ubiquitous component of treatment regimens for follicular non-Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells resist rituximab-mediated destruction remain unclear. Rituximab relies in part on immune effector mechanisms for its antitumor effect, and thus resistance may be mediated not only by
Andrew R, Rezvani, David G, Maloney
openaire   +2 more sources